New Delhi: Drug firm Lupin and US-based specialty pharmaceutical firm MonoSol Rx have signed a licensing agreement for multiple pediatric products.
Lupin Pharmaceutical Inc, the company's US subsidiary, and MonoSol Rx have entered into a licensing agreement wherein Lupin would develop multiple pediatric products utilising MonoSol Rx's PharmFilm drug delivery technology, Lupin said in a BSE filing.
Lupin Pharmaceuticals President Paul McGarty said: "Our alliance with MonoSol Rx will enable us to expand our family of pediatric products to help meet the needs of children for a variety of indications. We look forward to working with MonoSol Rx on the development of these products."
The agreement would be in line with focus on expanding into the specialty pharmaceutical market, and specifically pediatric needs such as attention-deficit/hyperactivity disorder (ADHD), Lupin said.
"We believe PharmFilm technology holds great promise for pediatric applications enabling increased compliance and adherence in a difficult to treat population," MonoSol Rx CEO Keith J Kendall said.
By partnering with Lupin, "we are taking a critical step forward in developing valuable and much-needed products," he added.
Shares of Lupin Ltd today closed at Rs 1,484.65 per scrip on BSE, down 0.44 percent from the previous close.